疾患エピゲノム制御分野Division of Disease Epigenetics

英文原著論文

  1. Harada T, Ohguchi H, Grondin Y, Kikuchi S, Sagawa M, Tai YT, Mazitschek R, Hideshima T, Anderson KC. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications. Leukemia. 2017 31(12):2670-77.
  2. Ohguchi H, Harada T, Sagawa M, Kikuchi S, Tai YT, Richardson PG, Hideshima T, Anderson KC. KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. Leukemia. 2017 31(12):2661-69.
  3. Sagawa M, Ohguchi H, Harada T, Samur MK, Tai YT, Munshi NC, Kizaki M, Hideshima T, Anderson KC. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 23(17):5225-37.
  4. Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 129(10):1308-19.
  5. Hideshima T, Qi J, Paranal RM, Tang W, Greenberg E, West N, Colling ME, Estiu G, Mazitschek R, Perry JA, Ohguchi H, Cottini F, Mimura N, Görgün G, Tai Yu-Tzu, Richardson PG, Carrasco RD, Wiest O, Schreiber SL, Anderson KC, Bradner J. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci USA. 2016 113(46):13162-67.
  6. Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 127(9):1138-50.
  7. Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, Samur MK, Mimura N, Suzuki R, Tai YT, Carrasco RD, Raje N, Richardson PG, Munshi NC, Harigae H, Sanda T, Sakai J, Anderson KC. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 7:10258.
  8. Suzuki R, Kikuchi S, Harada T, Mimura N, Minami J, Ohguchi H, Yoshida Y, Sagawa M, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi N, Ando K, Utsugi T, Hideshima T, Anderson KC. Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One. 2015 10(12):e0143847.
  9. Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 21(20):4607-18.
  10. Kikuchi S, Suzuki R, Ohguchi H, Yoshida Y, Lu D, Cottini F, Jakubikova J, Bianchi G, Harada T, Gorgun G, Tai YT, Richardson PG, Hideshima T, Anderson KC. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Leukemia. 2015 29(9):1918-27.
  11. Hideshima T, Cottini F, Ohguchi H, Jakubikova J, Gorgun G, Mimura N, Tai YT, Munshi NC, Richardson PG, Anderson KC. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer J. 2015 5:e312.
  12. Suzuki R, Hideshima T, Mimura N, Minami J, Ohguchi H, Kikuchi S, Yoshida Y, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi NC, Utsugi T, Anderson KC. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia. 2015 29(2):510-4.
  13. Cirstea D, Santo L, Hideshima T, Eda H, Mishima Y, Nemani N, Mahindra A, Yee A, Gorgun G, Hu Y, Ohguchi H, Suzuki R, Cottini F, Guichard SM, Anderson KC, Raje N. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. Mol Cancer Ther. 2014 13(11):2489-500.
  14. Nakajima S, Fujiwara T, Ohguchi H, Onishi Y, Kamata M, Okitsu Y, Fukuhara N, Ishizawa K, Harigae H. Induction of thymic stromal lymphopoietin in mesenchymal stem cells by interaction with myeloma cells. Leuk Lymphoma. 2014 55(11):2605-13.
  15. Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J, Cirstea D, Gorgun G, Minami J, Tai YT, Richardson PG, Utsugi T, Iwama A, Anderson KC. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 2014 74(16):4458-69.
  16. Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG, Hideshima T, Anderson KC. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 2014 28(3):680-9.
  17. Cirstea D, Hideshima T, Santo L, Eda H, Mishima Y, Nemani N, Hu Y, Mimura N, Cottini F, Gorgun G, Ohguchi H, Suzuki R, Loferer H, Munshi NC, Anderson KC, Raje N. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 27(12):2366-75.
  18. Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012 18(17):4669-81.
  19. Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, Kiziltepe T, Ikeda H, Kawano Y, French M, Blumenthal M, Tam V, Kertesz NL, Malyankar UM, Hokenson M, Pham T, Zeng Q, Patterson JB, Richardson PG, Munshi NC, Anderson KC. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood. 2012 119(24):5772-81.
  20. Ohguchi H, Ohba R, Onishi Y, Fukuhara N, Okitsu Y, Yamamoto J, Ishizawa K, Ichinohasama R, Harigae H. Successful treatment with bortezomib and thalidomide for POEMS syndrome. Ann Hematol. 2011 90(9):1113-4.
  21. Onishi Y, Sasaki O, Ichikawa S, Inokura K, Katsuoka Y, Ohtsuka Ohba R, Okitsu Y, Kohata K, Ohguchi H, Fukuhara N, Yokoyama H, Yamada MF, Yamamoto J, Ishizawa K, Kameoka J, Harigae H. Favorable outcome of unrelated cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2011 17(7):1093-7.
  22. Watanabe R, Shirai T, Tajima Y, Ohguchi H, Onishi Y, Fujii H, Takasawa N, Ishii T, Harigae H. Pregnancy-associated thrombotic thrombocytopenic purpura with anti-centromere antibody-positive Raynaud's syndrome. Intern Med. 2010 49(12):1229-32.
  23. Yokoyama H, Yamamoto J, Tohmiya Y, Yamada MF, Ohguchi H, Ohnishi Y, Okitsu Y, Fukuhara N, Ohba-Ohtsuka R, Kohata K, Ishizawa K, Kameoka J, Harigae H. Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type. Leuk Lymphoma. 2010 51(8):1509-12.
  24. Abe M, Yokoyama H, Tohmiya Y, Okitsu Y, Ohguchi H, Kohata K, Yamamoto J, Onishi Y, Ishizawa K, Kameoka J, Harigae H. Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy. Intern Med. 2009 48(20):1833-5.
  25. Ohguchi H, Sugawara T, Harigae H. Thrombotic thrombocytopenic purpura complicated with hypereosinophilic syndrome. Intern Med. 2009 48(18):1687-90.
  26. Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, Onishi Y, Fujiwara Yamada M, Ishizawa K, Kameoka J, Harigae H. A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression. Int J Hematol. 2009 89(3):342-7.
  27. Yamada MF, Miyamura K, Fujiwara T, Kohata K, Okitsu Y, Ohguchi H, Yamamoto J, Yokoyama H, Tomiya Y, Ishizawa K, Kameoka J, Harigae H. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis. Transplant Proc. 2008 40(10):3637-42.
  28. Ohguchi H, Tanaka T, Uchida A, Magoori K, Kudo H, Kim I, Daigo K, Sakakibara I, Okamura M, Harigae H, Sasaki T, Osborne TF, Gonzalez FJ, Hamakubo T, Kodama T, Sakai J. Hepatocyte nuclear factor 4alpha contributes to thyroid hormone homeostasis by cooperatively regulating the type 1 iodothyronine deiodinase gene with GATA4 and Kruppel-like transcription factor 9. Mol Cell Biol. 2008 28(12):3917-31.
  29. Sumi K, Tanaka T, Uchida A, Magoori K, Urashima Y, Ohashi R, Ohguchi H, Okamura M, Kudo H, Daigo K, Maejima T, Kojima N, Sakakibara I, Jiang S, Hasegawa G, Kim I, Osborne TF, Naito M, Gonzalez FJ, Hamakubo T, Kodama T, Sakai J. Cooperative interaction between hepatocyte nuclear factor 4 alpha and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8. Mol Cell Biol.2007 27(12):4248-60.
  30. Ohguchi H, Hirabayashi Y, Kodera T, Ishii T, Munakata Y, Sasaki T. Q fever with clinical features resembling systemic lupus erythematosus. Intern Med. 2006 45(5):323-6.
  31. Iguchi H, Ikeda Y, Okamura M, Tanaka T, Urashima Y, Ohguchi H, Takayasu S, Kojima N, Iwasaki S, Ohashi R, Jiang S, Hasegawa G, Ioka RX, Magoori K, Sumi K, Maejima T, Uchida A, Naito M, Osborne TF, Yanagisawa M, Yamamoto TT, Kodama T, Sakai J. SOX6 attenuates glucose-stimulated insulin secretion by repressing PDX1 transcriptional activity and is down-regulated in hyperinsulinemic obese mice. J Biol Chem. 2005 280(45):37669-80.
  32. Ohguchi H, Kameoka J, Harigae H, Yamada M, Tomiya Y, Takahashi S, Ishizawa K, Sano N, Sekine H, Sasaki T. Can the Helicobacter pylori eradication regimen induce platelet recovery in H. pylori-negative patients with idiopathic thrombocytopenic purpura? Am J Hematol. 2005 78(2):164-5.